Day: March 11, 2022

ลอนดอน, March 11, 2022 (GLOBE NEWSWIRE) — Emerging Markets Global Advisory Limited (EMGA) ธนาคารเพื่อการลงทุนเฉพาะทางที่เน้นตลาดเกิดใหม่ ประกาศในวันนี้ว่า จะดำเนินการเพิ่มทุนในรูปแบบหนี้อาวุโสที่สำคัญอีกครั้ง เพื่อให้ BTG Pactual สามารถขยายการให้สินเชื่อแก่วิสาหกิจขนาดกลางและขนาดเล็ก (SME) ในบราซิลต่อไปได้

JICA ได้ดำเนินการส่งมอบวงเงินกู้ 200 ล้านดอลลาร์สหรัฐ ซึ่งเป็นวงเงินกู้เพิ่มเติมหลังจากที่สถาบันเงินกู้เพื่อการพัฒนา (DFI) ให้กู้ยืมไปก่อนหน้านี้เป็นจำนวน 140 ล้านดอลลาร์สหรัฐและ 300 ล้านดอลลาร์สหรัฐตามลำดับ ซึ่งเป็นไปตามคำแนะนำของ EMGA เช่นกัน

โฆษกของ JICA กล่าวว่า “ด้วยความสนับสนุนของ EMGA เราจะเป็นพันธมิตรกับ Banco BTG Pactual S.A. เพื่อจัดการส่วนต่างของเงินช่วยเหลือสำหรับ MSME ในบราซิล BTG Pactual เป็นหนึ่งในบริษัทแรก ๆ ที่นำแพลตฟอร์มดิจิทัลมาใช้ เพื่อเสนอโซลูชันทางการเงินให้กับธุรกิจต่าง ๆ ทั่วทั้งประเทศ ด้วยแพลตฟอร์มดิจิทัลที่พร้อมรองรับการดำเนินงานด้านสินเชื่อของ Banco BTG Pactual S.A. บริษัทจึงสามารถขยายเครดิตให้แก่ธุรกิจต่าง ๆ ได้อย่างมีประสิทธิภาพในพื้นที่ภาคเหนือและภาคตะวันออกเฉียงเหนือ ซึ่งมีสถาบันทางการเงินเพียงไม่กี่แห่งที่ให้บริการอยู่ในขณะนี้”

Sajeev Chakkalakal กรรมการผู้จัดการและหัวหน้าฝ่ายวาณิชธนกิจของ EMGA กล่าวว่า “มีความยินดียิ่งที่ได้ช่วยเหลือทีมงานของบริษัท BTG อีกครั้งหนึ่ง โดยให้คำแนะนำในเรื่องวงเงินกู้เพิ่มเติมที่มีเป้าหมายเพื่อช่วยเหลือวิสาหกิจขนาดกลางและขนาดเล็กทั่วประเทศบราซิล JICA เป็นพันธมิตรสำคัญของ EMGA และในฐานะที่เป็นสถาบันทางการเงินเพื่อการพัฒนาที่โดดเด่น JICA ยังได้เสนอตัวเป็นแหล่งเงินทุนระยะยาวทางกลยุทธ์ใหม่ให้กับ BTG อีกแหล่งหนึ่งด้วย”

Jeremy Dobson กรรมการผู้จัดการและหัวหน้าฝ่ายพัฒนาธุรกิจของ EMGA ได้กล่าวเพิ่มเติมว่า “ทีมของเรายินดีที่ได้ทำหน้าที่เป็นที่ปรึกษาให้แก่ BTG อีกครั้ง และมุ่งหวังที่จะได้เห็นความสำเร็จที่ต่อเนื่องของบริษัท”

BTG Pactual:BTG เป็นธนาคารเพื่อการลงทุนที่ใหญ่ที่สุดในละตินอเมริกา และใหญ่เป็นอันดับ 6 ในบราซิลตามมูลค่าส่วนของผู้ถือหุ้น และมีบทบาทสำคัญในการให้เงินกู้ และค้ำประกันให้แก่ลูกค้าที่หลากหลายตั้งแต่ SME จนถึงบรรษัทขนาดใหญ่ BTG เป็นผู้บุกเบิกด้านการส่งเสริมการเงินเพื่อการเปลี่ยนแปลงสภาพภูมิอากาศในบราซิล และมีบทบาทหลักในการจัดหาช่องทางด้านเงินทุนสำหรับโครงการต่าง ๆ เพื่อให้เกิดผลในเชิงบวกต่อชุมชน

JICA:องค์กรความร่วมมือระหว่างประเทศของญี่ปุ่น เป็นหน่วยงานรัฐที่ให้ความช่วยเหลือด้านการพัฒนาอย่างเป็นทางการของรัฐบาลญี่ปุ่น ซึ่งก่อตั้งขึ้นตามกฎหมายด้วยวัตถุประสงค์ที่จะให้ความช่วยเหลือเพื่อการเติบโตทางเศรษฐกิจและสังคมในประเทศกำลังพัฒนา และส่งเสริมความร่วมมือระหว่างประเทศ

Emerging Markets Global Advisory Limited (EMGA)ซึ่งมีสำนักงานในลอนดอนและนิวยอร์ก ให้บริการช่วยเหลือสถาบันทางการเงินและบริษัทต่าง ๆ ที่ต้องการระดมทุนในรูปแบบตราสารหนี้หรือตราสารทุน ทีมงานนานาชาติของ EMGA รวบรวมประสบการณ์ที่สั่งสมมาหลายสิบปี เพื่อทำธุรกรรมในนามของลูกค้าในตลาดเกิดใหม่และเศรษฐกิจชายขอบให้ลุล่วง ซึ่งรวมถึงบราซิลที่ยังคงเป็นตลาดสำคัญของบริษัท ด้วยผลงานอันเป็นที่ประจักษ์ด้านการจัดหาเงินทุนและการให้คำปรึกษาเชิงกลยุทธ์ในวัฏจักรเศรษฐกิจที่หลากหลาย EMGA ยังคงขยายการดำเนินงานและเสนอบริการออกไปอย่างต่อเนื่อง เพื่อสร้างจุดยืนที่มั่นคงในตลาดในฐานะธนาคารเพื่อการลงทุนเฉพาะทางที่เน้นตลาดเกิดใหม่สำหรับอุตสาหกรรมที่โดดเด่น

ติดต่อสอบถามได้ที่info@emergingmarketsglobaladvisory.com

Richard Kay
richard.kay@okx.com

March 11, 2022

• Industry first integrated, diagnostic quality tele-ultrasound technology lets clinicians talk, text, screen share, and transfer control to remote colleagues in real time
• New functionality helps increase diagnostic confidence on compatible clients including iOS, Android, Chrome web browser and Windows
• Peer reviewed data on efficacy and efficiency presented at the American Institute of Ultrasound in Medicine Annual Meeting

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that Collaboration Live has received expansion of its U.S. Food & Drug Administration 510(k) market clearance for remote diagnostic use on additional mobile platforms. Available on Philips Ultrasound Systems EPIQ and Affiniti [1], Collaboration Live allows clinicians to collaborate in real-time with colleagues in order to complete image acquisition and diagnosis regardless of location.

Ultrasound imaging is one of the most accessible and low-cost imaging modalities. However, capturing and interpreting the acquired images and making an accurate diagnosis requires a great deal of expertise and skill. While ultrasound equipment is readily available both in hospitals and healthcare settings, widespread staffing shortages can impede access to care. In addition, the COVID-19 pandemic highlighted the risk to clinicians in contact with infectious patients, and the resulting backlog of postponed exams is now increasing workloads and driving the need for greater efficiency. Collaboration Live enables remote diagnosis, expanding the ability to image patients inside and outside of healthcare facilities, and could help limit the risk of exposure for healthcare workers and patients to infectious diseases such as COVID-19.

With its expanded clearance for diagnostic use on additional platforms, clinicians now have the ability to consult or diagnose from their mobile device, check the strength of their bandwidth before making a call, and check their remote screen calibration to ensure image quality is appropriate for diagnosis. This can enable greater efficiency and flexibility for clinicians since they are no longer limited to a PC for remote collaboration.

Collaboration Live is already helping to extend access to quality care in underserved settings. “We have been able to open a strictly telemedicine office to serve our patients in rural communities because Collaboration Live enables us to carry out a full diagnostic patient visit remotely,” said Michael S. Ruma, MD, MPH, at Perinatal Associates of New Mexico, who will present peer-reviewed data on the associated return-on-investment at this year’s American Institute of Ultrasound in Medicine Annual Meeting (AIUM 2022).

“We are committed to helping our customers deliver better access to care for their patients regardless of their location at any time. Collaboration Live is a perfect example of how Philips is delivering an expanded experience for patients and healthcare professionals through telemedicine”, said Gerois Di Marco, General Manager Global Ultrasound Services & Solutions at Philips. “Sonographers no longer have to feel they are alone or limited to only acquiring ultrasound images and preparing a report for subsequent clinical review. They can now call on the expertise of colleagues during ultrasound examinations to deliver on-the-spot accurate diagnosis that every patient deserves.”

Philips Collaboration Live lets users quickly and securely talk, text, screen-share, and video-stream directly from a Philips Ultrasound System EPIQ or Affiniti to a compatible remote PC or mobile device [1]. In addition to allowing remote clinicians to view real-time diagnostic ultrasound images and communicate with the local clinician and patient to provide guidance and ask questions, the ultrasound user can give remote control [2] of the ultrasound system to the remote user, enabling them to enhance image quality, capture a new image or make a measurement. These combined features as well as the ability to check the calibration of the remote viewing screen provide the high diagnostic confidence needed to help optimize patient outcomes.

Collaboration Live can help hospitals standardize care across locations and support remote staff via protocol training, remote support during ultrasound examinations, and real-time communication between clinicians and patients, helping to ensure the same high standard of care wherever it is delivered. Collaboration Live is applicable in any area of medicine – such as breast imaging and hepatology, where ultrasound can provide important diagnostic information – including maternal fetal medicine when dealing with the potential of high-risk pregnancies, as well as cardiac imaging.

Visit AIUM 2022 for more detail about Philips participation in the event, and visit Philips advanced tele-ultrasound solutions for more information on Philips Collaboration Live and other solutions in the company’s advanced ultrasound portfolio.

[1] Requires an EPIQ or Affiniti ultrasound system with software level 7.0.5. or higher. Mobile access via compatible clients including iOS, Android, Chrome web browser and Windows for diagnostic use requires Collaboration Live 9.0 or higher.
[2] Remote control requires a Windows device. Collaboration Live is available in the USA, and select availability in other countries.

For further information, please contact:

Kathy O’Reilly
Philips Global Press Office
Tel.: +1 978-221-8919
E-mail : kathy.oreilly@philips.com
Twitter: @kathyoreilly

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2021 sales of EUR 17.2 billion and employs approximately 78,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachment

• Clinicians collaborating over virtual chat

LONDON, March 11, 2022 (GLOBE NEWSWIRE) — Caribbean nations are becoming investment hubs in the global arena, offering attractions such as safety, lucrative financial diversification options and of course idyllic lifestyles that make them desirable places to take up second citizenship. This is according to the World Citizenship Report (WCR), which ranked countries that provide citizenship by investment (CBI) options in the region in the top 30 per cent.

The new one-of-a-kind report was developed by CS Global Partners, the world’s leading government advisory and marketing firm. The WCR measures 187 countries against five motivators that are relevant amongst High Net-Worth Individuals (HNWIs). These motivators include Safety and Security, Economic Opportunity, Quality of Life, Global Mobility and Quality of Life.

The report considers data from the Global Peace Index (GPI) 2021 and World Governance Indicators (WGI) and scored the Caribbean region highly in the Safety and Security, Quality of Life and Global Mobility motivators.

The Caribbean is considered the cradle of investment immigration due to the high concentration of countries that offer CBI programmes in the region. These countries’ proximity in the WCR ranking reflects a sense of community and collaboration that characterises nations in the jurisdiction.

For example, all the Caribbean nations hosting CBI programmes are members of CARICOM, which is committed to promoting and supporting a unified Caribbean community that is inclusive, resilient, and competitive to share in economic, social, and cultural growth.

At its 33^rd meeting, CARICOM members pledged to continue to be vigilant in managing the threats to sustainable development in the region. This included implementing initiatives that attract foreign direct investment, ensuring that the region is not perceived as high risk by investors, lobbying against the proposed global minimum corporation tax and continuing to build relations with the OECD and European Union.

The Chair of the Conference, the Prime Minister of Belize, the Honourable John Briceño, stated that the 33rd Inter-Sessional Meeting was a particularly consequential meeting which was taking place at a time when “unprecedented and existential challenges coincide with our citizens’ expectations for relief and prosperity.”

“We are contending with the worst economic recession in modern history and to foster our recovery, we need to rekindle the founding vision of CARICOM, both with respect to the scale of its ambition for integration, and the speed which was needed to achieve its consolidation. Our recovery should be aligned to a new regional agenda that is centred around creating prosperity for the people,” he continued.

In order to achieve this prosperity for the people, heads of government at CARICOM also agreed that the immediate and urgent implementation of the CARICOM Single Market and Economy or CSME was imperative for responding to the current developmental challenges and for building a more resilient region.

Another way that small island nations are ensuring their prosperity and sustainability is through CBI programmes. CBI is a well-documented and viable way for Caribbean nations to attract FDI into their economies which can then be used for significant developmental projects.

For example, the island nation of Dominica is constructing a geothermal plant that is expected to be operational by 2023 in partnership with the United Kingdom, the World Bank and Kenesjay Green LTD, a local green energy company. The plant will ensure that the country is powered by renewable energy, reducing energy costs and carbon emissions while simultaneously creating jobs.

In St Kitts and Nevis, the construction of the second cruise pier at Port Zante was financed via various local and international sources, of which US$5 million came from the country’s CBI. The pier has allowed St Kitts and Nevis to host the world’s largest cruise vessels, which has been particularly important for the tourism sector. The small but ambitious Caribbean country now has the marquee status of larger cruise destinations in the region.

The inflow of funds to the private sector have had a noticeable impact on the economic activity of island nations, in many instances improving fiscal outcomes, facilitating debt repayment, and spurring economic growth.

Research by the International Monetary Fund (IMF) found that CBI programmes are having a significant macroeconomic impact on these countries. From a country perspective, CBI contributed more than 30 per cent of GDP in St Kitts and Nevis in 2020. According to Les Khan, CBI Unit Head of St Kitts and Nevis, the Programme’s revenue was a “main driver” during lockdown when tourism was at an all-time low.

While in Dominica, the IMF noted that the “strong growth” in the construction sector was “financed with record-high CBI revenue of 30 per cent of GDP” in 2021.

In 2017, CBI accounted for 20 per cent of the GDP in Antigua and Barbuda – showing that inflows from CBI programmes are making a major difference in the performance of government of smaller countries.

Taking a deeper dive into some notable CBI programmes in the region, St Kitts and Nevis established their CBI Programme in 1984 and is the longest-running in the world.

Being the first of its kind, the Programme is also one of the most reputable and has become known as the ‘Platinum Standard’ brand in the industry. After over three decades, the twin-island nation continues to be a popular option for investors and their families due to its longevity and commitment to due diligence processes.

The country scored a respectable score of 66.8 points out of 100 in the overall rankings in the WCR, the highest of all the Caribbean CBI nations. It reached top marks in the Safety and Security, Quality of Life and Global Mobility motivators.

Dominica’s CBI Programme was launched in 1993 and has been ranked as the number one CBI initiative for five consecutive years in the CBI Index, published by the Financial Times’ Professional Wealth Management magazine. The nation is politically and economically stable, with a low crime rate and rich investment opportunities.

Known as the Nature Isle, Dominica placed in the 52nd spot, achieving high marks for Safety and Security, Quality of Life and Global Mobility motivators.

Contact Details:

pr@csglobalpartners.com
www.csglobalpartners.com
+447824029952

March 10, 2022

Amsterdam, the Netherlands – Royal Philips’ (NYSE: PHG, AEX: PHIA) subsidiary, Philips Respironics, today provided an update on the remediation status in the US of the ongoing recall of certain sleep and respiratory care products in connection with identified potential health risks related to the polyester-based polyurethane (PE-PUR) sound abatement foam in these devices.

Customer and patient outreach
Following two rounds of comprehensive customer and patient outreach, Philips Respironics has reached the vast majority of the installed base in the US resulting in the registration of approximately 2.6 million devices in the country. Philips Respironics continues to monitor recall awareness for affected patients [1]. Philips Respironics is working cooperatively with the US Food and Drug Administration (FDA) to further increase awareness for patients, consumers, and healthcare providers of the recall. Based on feedback from the FDA, Philips Respironics will be working with its DME customers to allow the company to directly contact those patients and other end-users that may not yet have received notice of the recall.

In addition, Philips Respironics continues to utilize its current mobile application, DreamMapper, to send notifications to patients and consumers utilizing the application with information regarding the field action. The DreamMapper notification function is used to direct patients/consumers back to the field action website, which includes detailed information on the field action and the process for registering, and maintaining such registration, for a replacement device.

Repair and replacement program
To date, Philips Respironics has shipped a total of more than 650,000 replacement devices to customers in the US, and aims to complete the repair and replacement program in the fourth quarter of 2022.

Test and research program
In December 2021, Philips provided an update on the VOC test results to-date for the first-generation DreamStation devices [2]. The results indicate that the VOC concentrations are within safe exposure limits specified in the applicable safety standard (ISO 18562). Comprehensive particulate testing and analyses for the first-generation DreamStation devices are expected to be completed in the second quarter of 2022.

Initial testing results suggest that PE-PUR foam degradation in CPAP devices is accelerated by repeated exposure to ozone cleaning. The FDA and Philips have communicated and reiterated that ozone is not an approved cleaning agent. For example, as directed by FDA, Philips has prominently published information on the risk of using ozone cleaners on the landing page of the Philips Respironics field action website.

Philips is working cooperatively with the FDA and other competent authorities to update them on new test data as they become available. Philips is also working cooperatively with the FDA to develop a consolidated summary for healthcare providers on the available, finalized testing data, results, and conclusions, which will be updated as new test data becomes available.

Independent of Philips Respironics, in December 2021, an analysis was published in the American Journal of Respiratory and Critical Care Medicine [2] that did not find a higher risk of incident cancer among obstructive sleep apnea (OSA) patients who used a Philips Respironics PAP device as compared to OSA patients who used a PAP device from other manufacturers, or OSA patients without treatment. The analysis and conclusion were based on data from a large multicenter cohort study involving 6,900 OSA patients on PAP devices between 2012 and 2020, including 1,200 Philips Respironics PAP users. Philips Respironics was not involved in the study or the analysis.

[1] Philips Respironics’ monthly surveys indicate that nearly 80% (aggregate data) of responding Philips Respironics CPAP users in the US confirmed they were aware of the recall. Each study was conducted online on a national representative sample of 2,200 adults (and weighted based on age, gender, race, and education level). Results have a margin of error of +/- 2% at a 95% confidence level for the overall population.

[2] The vast majority of the registered affected devices in the US to date are in the first-generation DreamStation product family.

[3] An Association between Positive Airway Pressure Device Manufacturer and Incident Cancer? A Secondary Data Analysis; American Journal of Respiratory and Critical Care Medicine, 2021, Volume 204, Issue 12 pp. 1484–1488; Tetyana Kendzerska, Richard S. Leung, Mark I. Boulos, Daniel I. McIsaac, Brian J. Murray, Gregory L. Bryson, Robert Talarico, Atul Malhotra, Andrea S. Gershon, Constance Mackenzie, and Marcus Povitz. The analysis can be found here.

For further information, please contact:

Steve Klink
Philips Global Press Office
Tel.: +31 6 10888824
E-mail: steve.klink@philips.com

Derya Guzel
Philips Investor Relations
Tel.: +31 20 59 77055
E-mail: derya.guzel@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2021 sales of EUR 17.2 billion and employs approximately 78,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Forward-looking statements
This statement contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.

Nyxoah to Participate in the Oppenheimer 32^nd Annual Healthcare Conference

Mont-Saint-Guibert, Belgium – March 10, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will present at the Oppenheimer 32^ndAnnual Healthcare Conference, which will be held virtually from March 15-17, 2022.

Olivier Taelman, Nyxoah’s Chief Executive Officer, is scheduled to present a corporate update on Wednesday, March 16, 2022, at 10:40am EST. Please click here to access the live webcast of the presentation. The webcast will also be available on the Eventspage of Nyxoah’s investor relations website.

Nyxoah’s updated Investor Presentation can be accessed on the Shareholder Information section of the Company’s Investor Relations page.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Contacts:
Nyxoah
Loic Moreau, Chief Financial Officer
corporate@nyxoah.com
+32 473 33 19 80

Jeremy Feffer, VP IR and Corporate Communications
jeremy.feffer@nyxoah.com
+1 917 749 1494

Attachment

• ENGLISH_Opco Conference PR_FINAL